Suman Nag

Suman Nag joined Flagship Pioneering in 2025 as Director of Cardiovascular for Pioneering Medicines. He is responsible for leading a research-focused team dedicated to developing innovative therapies to address serious cardiovascular and cardiometabolic unmet needs. He also supports several functional teams across all stages of drug discovery, from preclinical research to early clinical development, to advance a pipeline of innovative therapies.

Suman has nearly ten years of experience in drug discovery, working across various therapeutic areas and modalities within the pharmaceutical industry. His expertise includes oncology, cardiovascular, and infectious diseases. Previously, Suman served as Co-President and Director of Research at Kainomyx, Inc., where he contributed to drug discovery for global health indications. Before that, as Associate Director and in related roles at MyoKardia (later acquired by Bristol Myers Squibb), he played a key role in uncovering the molecular mechanisms behind hypertrophic cardiomyopathy and in the discovery and development of the first-in-class FDA-approved drug, Camzyos, as well as discovering and developing several clinical assets, such as Danicamtiv, a small-molecule cardiac activator for dilated cardiomyopathy.

He is a biotech entrepreneur and co-founded two biotech ventures, including Kainomyx, Inc., which is actively developing novel small-molecule therapies for malaria and other infectious diseases in animals. Suman has co-authored multiple publications in renowned peer-reviewed journals like Science, Nature, and PNAS, and holds several patents.

Suman earned his Ph.D. in Chemistry from the Tata Institute of Fundamental Research in India and completed a postdoctoral fellowship at Stanford University.